Deals Shaping The Medical Industry, October 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
You may also be interested in...
EMA Doubles Number Of EU Early Access Approval Recommendations
The EU’s special provisions for speeding new products towards approval proved more popular than ever with drug sponsors last year.
BI/Lilly's Jardiance Takes On AstraZeneca's Farxiga With Heart Failure Approval
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.
Sartans Recalled In UK As Further Impurity Is Confirmed
Certain batches of two angiotensin II receptor blockers, or sartans, are being recalled in the UK after an impurity that can potentially increase the risk of cancer over time was detected.